Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma

被引：12

作者：

Sanchez, Diana ^{[1
]}

Pelayo, Rosana ^{[2
]}

Alberto Medina, Luis ^{[3
]}

Vadillo, Eduardo ^{[2
]}

Sanchez, Rogelio ^{[4
]}

Nunez, Luis ^{[1
]}

Cesarman-Maus, Gabriela ^{[5
]}

Elena Sarmiento-Silva, Rosa ^{[1
]}

机构：

[1] Univ Nacl Autonoma Mexico, Fac Vet Med & Anim Husb, Mexico City 04510, DF, Mexico

[2] Mexican Inst Social Secur, Oncol Hosp, Med Res Unit, Mexico City 06720, DF, Mexico

[3] Univ Nacl Autonoma Mexico, Natl Canc Inst & Phys Inst, Biomed Canc Res Unit, Mexico City 14080, DF, Mexico

[4] Spanish Hosp, Dept Pathol, Mexico City 11520, DF, Mexico

[5] Natl Canc Inst, Dept Hematol, Mexico City 14080, DF, Mexico

来源：

VIRUSES-BASEL | 2016年 / 8卷 / 01期

关键词：

Newcastle disease virus; lymphoma; oncolytic virus; NON-HODGKIN-LYMPHOMA; ONCOLYTIC VIROTHERAPY; DRUG DEVELOPMENT; TUMOR-CELLS; CANCER; DOGS; REPLICATION; MODELS; PV701; INTERLEUKIN-2;

D O I：

10.3390/v8010003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Research on oncolytic viruses has mostly been directed towards the treatment of solid tumors, which has yielded limited information regarding their activity in hematological cancer. It has also been directed towards the treatment of humans, yet veterinary medicine may also benefit. Several strains of the Newcastle disease virus (NDV) have been used as oncolytics in vitro and in a number of in vivo experiments. We studied the cytolytic effect of NDV-MLS, a low virulence attenuated lentogenic strain, on a human large B-cell lymphoma cell line (SU-DHL-4), as well as on primary canine-derived B-cell lymphoma cells, and compared them to healthy peripheral blood mononuclear cells (PBMC) from both humans and dogs. NDV-MLS reduced cell survival in both human (42% +/- 5%) and dog (34% +/- 12%) lymphoma cells as compared to untreated controls. No significant effect on PBMC was seen. Cell death involved apoptosis as documented by flow-cytometry. NDV-MLS infections of malignant lymphoma tumors in vivo in dogs were confirmed by electron microscopy. Early (24 h) biodistribution of intravenous injection of 1 x 10(12) TCID50 (tissue culture infective dose) in a dog with T-cell lymphoma showed viral localization only in the kidney, the salivary gland, the lung and the stomach by immunohistochemistry and/or endpoint PCR. We conclude that NDV-MLS may be a promising agent for the treatment of lymphomas. Future research is needed to elucidate the optimal therapeutic regimen and establish appropriate biosafety measures.

引用

页数：12

共 46 条

[1]

Berger FJA, 2009, VET MEXICO, V40, P141

[2]

[Anonymous], CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735IMA03BS21

[3]

[Anonymous], 2012, FRONT PSYCHOL, DOI DOI 10.3389/FPSYG.2012.00234

[4] Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy [J].

Bai, Fuliang ;

Niu, Zeshan ;

Tian, Hui ;

Li, Siming ;

Lv, Zheng ;

Zhang, Tianyuan ;

Ren, Guiping ;

Li, Deshan .

IMMUNOLOGY LETTERS, 2014, 159 (1-2) :36-46

[5] Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells [J].

BarEli, N ;

Giloh, H ;

Schlesinger, M ;

ZakayRones, Z .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (07) :409-415

[6] Effects of social support by a dog on stress modulation in male children with insecure attachment [J].

Beetz, Andrea ;

Julius, Henri ;

Turner, Dennis ;

Kotrschal, Kurt .

FRONTIERS IN PSYCHOLOGY, 2012, 3

[7] Incorporation of Host Complement Regulatory Proteins into Newcastle Disease Virus Enhances Complement Evasion [J].

Biswas, Moanaro ;

Johnson, John B. ;

Kumar, Sandeep R. P. ;

Parks, Griffith D. ;

Subbiah, Elankumaran .

JOURNAL OF VIROLOGY, 2012, 86 (23) :12708-12716

[8] Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy [J].

Buijs, P. R. A. ;

van Amerongen, G. ;

van Nieuwkoop, S. ;

Bestebroer, T. M. ;

van Run, P. R. W. A. ;

Kuiken, T. ;

Fouchier, R. A. M. ;

van Eijck, C. H. J. ;

van den Hoogen, B. G. .

CANCER GENE THERAPY, 2014, 21 (11) :463-471

[9] Oncolytic viruses: From bench to bedside with a focus on safety [J].

Buijs, Pascal R. A. ;

Verhagen, Judith H. E. ;

van Eijck, Casper H. J. ;

van den Hoogen, Bernadette G. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) :1573-1584

[10] Species D Adenoviruses as Oncolytics against B-cell Cancers [J].

Chen, Christopher Y. ;

Senac, Julien S. ;

Weaver, Eric A. ;

May, Shannon M. ;

Jelinek, Diane F. ;

Greipp, Philip ;

Witzig, Thomas ;

Barry, Michael A. .

CLINICAL CANCER RESEARCH, 2011, 17 (21) :6712-6722

← 1 2 3 4 5 →